- Home
- NESR vs ERAS Comparison
NESR vs ERAS Comparison
Compare NESR & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NESR
- ERAS
- Stock Information
- Founded
- NESR 2017
- ERAS 2018
- Country
- NESR United States
- ERAS United States
- Employees
- NESR 6231
- ERAS N/A
- Industry
- NESR
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- NESR
- ERAS Health Care
- Exchange
- NESR NYSE
- ERAS Nasdaq
- Market Cap
- NESR 895.3M
- ERAS 723.8M
- IPO Year
- NESR N/A
- ERAS 2021
- Fundamental
- Price
- NESR $9.38
- ERAS $1.90
- Analyst Decision
- NESR Strong Buy
- ERAS Strong Buy
- Analyst Count
- NESR 3
- ERAS 5
- Target Price
- NESR $14.33
- ERAS $5.70
- AVG Volume (30 Days)
- NESR 130.7K
- ERAS 1.5M
- Earning Date
- NESR 11-19-2024
- ERAS 11-12-2024
- Dividend Yield
- NESR N/A
- ERAS N/A
- EPS Growth
- NESR N/A
- ERAS N/A
- EPS
- NESR 0.54
- ERAS N/A
- Revenue
- NESR $1,265,542,000.00
- ERAS N/A
- Revenue This Year
- NESR $15.10
- ERAS N/A
- Revenue Next Year
- NESR $7.81
- ERAS N/A
- P/E Ratio
- NESR $17.18
- ERAS N/A
- Revenue Growth
- NESR 39.14
- ERAS N/A
- 52 Week Low
- NESR $7.68
- ERAS $1.64
- 52 Week High
- NESR $9.89
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- NESR N/A
- ERAS 29.70
- Support Level
- NESR N/A
- ERAS $1.77
- Resistance Level
- NESR N/A
- ERAS $2.84
- Average True Range (ATR)
- NESR 0.00
- ERAS 0.18
- MACD
- NESR 0.00
- ERAS -0.07
- Stochastic Oscillator
- NESR 0.00
- ERAS 12.15
About NESR NATIONAL ENERGY SVCS REUNITED CORP
National Energy Services Reunited Corp is a British Virgin Islands-based company engaged in providing products and services to the oil and gas industry in the Middle East and North Africa and the Asia Pacific regions. The company has two reportable segments: Production Services including coil tubing, stimulation, and pumping, nitrogen services, completions, pipelines, cementing, laboratory services and filtration services; and Drilling and Evaluation Services including drilling and workover rigs, rig services, services, and well-testing services among others. Revenues are majorly derived from production services of an oil or natural gas well.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.